UNCY Q3 EPS Forecast Raised by Brookline Capital Management

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) – Investment analysts at Brookline Capital Management lifted their Q3 2025 earnings per share (EPS) estimates for Unicycive Therapeutics in a research report issued on Tuesday, June 10th. Brookline Capital Management analyst K. Raja now anticipates that the company will post earnings per share of ($0.05) for the quarter, up from their prior forecast of ($0.07). The consensus estimate for Unicycive Therapeutics’ current full-year earnings is ($0.23) per share. Brookline Capital Management also issued estimates for Unicycive Therapeutics’ Q4 2025 earnings at ($0.06) EPS, FY2025 earnings at ($0.15) EPS, FY2026 earnings at ($0.08) EPS, FY2027 earnings at $0.63 EPS, FY2028 earnings at $0.85 EPS and FY2029 earnings at $1.01 EPS.

Other analysts have also issued reports about the company. HC Wainwright raised Unicycive Therapeutics to a “strong-buy” rating and set a $9.00 price target on the stock in a research note on Tuesday, May 27th. Guggenheim initiated coverage on Unicycive Therapeutics in a research note on Monday, April 21st. They issued a “buy” rating and a $6.00 price target on the stock.

Unicycive Therapeutics Trading Up 18.4%

Shares of NASDAQ:UNCY opened at $0.63 on Thursday. The stock’s 50-day moving average price is $0.61 and its two-hundred day moving average price is $0.63. Unicycive Therapeutics has a 12-month low of $0.20 and a 12-month high of $1.10. The firm has a market cap of $75.98 million, a price-to-earnings ratio of -0.65 and a beta of 2.01.

Unicycive Therapeutics (NASDAQ:UNCY) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.09.

Hedge Funds Weigh In On Unicycive Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Northern Trust Corp lifted its stake in shares of Unicycive Therapeutics by 142.4% in the 4th quarter. Northern Trust Corp now owns 58,181 shares of the company’s stock valued at $46,000 after purchasing an additional 34,183 shares in the last quarter. Nantahala Capital Management LLC lifted its stake in shares of Unicycive Therapeutics by 268.5% in the 4th quarter. Nantahala Capital Management LLC now owns 10,391,994 shares of the company’s stock valued at $8,253,000 after purchasing an additional 7,571,636 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of Unicycive Therapeutics by 30.3% in the 4th quarter. Geode Capital Management LLC now owns 524,487 shares of the company’s stock valued at $417,000 after purchasing an additional 122,089 shares in the last quarter. XTX Topco Ltd raised its holdings in shares of Unicycive Therapeutics by 142.2% during the 4th quarter. XTX Topco Ltd now owns 171,463 shares of the company’s stock valued at $136,000 after buying an additional 100,679 shares during the period. Finally, Vivo Capital LLC raised its holdings in shares of Unicycive Therapeutics by 123.0% during the 4th quarter. Vivo Capital LLC now owns 9,970,152 shares of the company’s stock valued at $7,918,000 after buying an additional 5,500,000 shares during the period. 40.42% of the stock is owned by institutional investors and hedge funds.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.